ADNI3 (H-39481)

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3)

The Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3) will test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be used together to measure progression in mild cognitive impairment (MCI) and Alzheimer’s disease (AD).

Neuroimaging research suggests that PET and MRI may be a more precise tool in assessing disease progression than traditional neuropsychological assessments. Standardizing the way neuroimaging is done would make it easier for researchers to compare studies, develop new treatments and monitor their effectiveness.

Eligibility: Participants from ongoing ADNI2 study will rollover to the ADNI3 study. New subjects will also be recruited in five (3) groups:

1. Cognitively Normal (CN)
2. Mild Cognitive Impairment (MCI)
3. Alzheimer’s Disease (AD)

For all new recruits, a person is eligible if he or she:

• Is between age 55 and 90 and in good general health
• Has an informant, who has frequent contact, and who is available to accompany the participant to all visits
• Meets other specific general health and cognitive function criteria for each group